Clinical trial NCT04715737: Differential Effects of Vasopressin and Oxytocin on Attention Control
Official title: The Differential Effects of Intranasal Vasopressin and Oxytocin on Attention Control
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Vasopressin
Oxytocin
Eye-tracking
Attention control
Lead sponsor: University of Electronic Science and Technology of China
Sponsor class: OTHER
First posted: 2021-01-20
Enrollment: 160
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design
Primary purpose: BASIC_SCIENCE

Brief summary: The main aim of the present study is to investigate whether intranasal vasopressin (20IU) and oxytocin (24IU) have differential effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Detailed description: Previous studies have demonstrated intranasal vasopressin and oxytocin's divergent effects on social behavior and emotion processing such as empathy and negative emotion processing, however, it remains unclear whether vasopressin and oxytocin treatment would have differential effects on attention processing to social stimuli. Based on the previous registered studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) from our group using a validated emotional anti-saccade task with social stimuli (emotional faces) and non-social stimuli (oval shape) have separately explored intranasal vasopressin and oxytocin's modulatory effects on attention processing, the present study aims to conduct a secondary analysis of the previously acquired data to directly compare vasopressin and oxytocin's effects on attention control to social emotional stimuli. To this end data from subjects who underwent intranasal oxytocin administration (n = 33; NCT03486925) will be compared with data from subjects who underwent intranasal vasopressin or placebo administration (n = 39, or 45 respectively; NCT04493554). To further control for non-treatment related factors the intranasal placebo groups from the previous studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) will be compared with respect to primary and secondary outcome measures of the trial, in particular general and emotion-specific effects on attentional control.

Eligibility criteria: Inclusion Criteria:

* Male, healthy participants
* Non smokers

Exclusion Criteria:

* Previous or current medical, psychiatric, neurological disorder
* Regular medication
* Use of any psychoactive substances in the 24 hours before experiment

Primary outcomes:
measure: Differential effects of intranasal vasopressin and oxytocin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli
timeFrame: Time Frame: 45 minutes - 100 minutes after treatment
measure: Differential effects of intranasal vasopressin and oxytocin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli
timeFrame: Time Frame: 45 minutes - 100 minutes after treatment
Secondary outcomes:
measure: Emotion-specific effects of vasopressin and oxytocin administration on saccade/antisaccade latencies towards the separate facial emotions
timeFrame: Time Frame: 45 minutes - 100 minutes after treatment
measure: Emotion-specific effects of vasopressin and oxytocin administration on saccade/antisaccade error rates for the separate facial emotions
timeFrame: Time Frame: 45 minutes - 100 minutes after treatment
Other outcomes:
Locations:
city: Sichuan
country: China
facility: University of Electronic Science and Technology of China (UESTC)
state: Chengdu
Study officials:
affiliation: University of Electronic Science and Technology of China (UESTC)
name: Keith Kendrick, PhD
role: PRINCIPAL_INVESTIGATOR
References: